The Drug Controller General of India's subject expert committee (SEC) has given its approval to Bharat Biotech to conduct a trial that will involve combining the doses of Covaxin and Hyderabad-based firm's other nasal COVID-19 vaccine.
Bharat Biotech, which manufactures Covaxin, is presently conducting trials of its intranasal COVID-19 vaccine in the country.
The SEC has given its go-ahead to Bharat Biotech to conduct the phase 2 and 3 clinical trials, adminisering a dose each of Covaxin and the adenoviral intranasal vaccine with an interval between the two, reports Economic Times.
"After detailed deliberation, the committee recommended grant of permission for conduct of the proposed clinical trial removing the word 'interchangeability' from the study title," the minutes of SEC's meeting held on Thursday (29 July) said.
It should be noted that Bharat Biotech's intranasal vaccine is the first of its kind COVID-19 jab to undergo trials in India.
The Hyderabad-based firm is developing a single-dose nasal Covid-19 vaccine in partnership with US-based Washington University.
Earlier on Thursday (29 July), Bharat Biotech chairman Krisna Ella said at a FICCI event that the combination of the two jabs could be a game-changer.
He added that the production of the nasal vaccine can be scaled up easily and that the company can produce 10 crore doses a month.
The company reportedly expects to gather significant data from its studies on the intranasal COVID-19 vaccine in the next two-and-a-half months.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.